From: Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Enrolled patients, No. (evaluable) | 41 (39) |
Median Age, Y (Range) | 62 (36–83) |
Sex | 34 F, 7 M |
Race/ethnicity | 14 W, 3 AA, 1 A, 23 Ha |
Median No. of prior regimens (range) | 2 (1–7) |
Primary diagnosis | |
 Ovarian | 11 |
 Endometrial | 9 (2 carcino-sarcomas) |
 Pancreatic | 2 |
 Colorectal | 4 (1 neuro-endocrine) |
 Cervical | 2 |
 Fallopian | 2 |
 Vaginal | 2 |
 Head and neck | 2 (1 adenoid cystic), |
 Breast, esophagus, small-cell lung, small bowel, thymic, vulvar, Mullerian | 1 each |